India to Netherlands: Albendazole Export Trade Route

To import Albendazole formulations into the Netherlands, the following approvals and registrations are necessary:

• Marketing Authorization Application (MAA): Applicants must submit an MAA in the Common Technical Document (CTD) or electronic CTD (eCTD) format. This comprehensive dossier includes quality, safety, and efficacy data.

• Approval Timelines: The evaluation process for an MAA typically spans 210 days, excluding any clock stops for additional information requests.

• Product Registration Fees: Fees vary based on the type of application and the specific procedures involved.

• Good Manufacturing Practice (GMP) Compliance: Manufacturing facilities, including those in India, must comply with EU GMP standards. The EMA or national competent authorities may conduct inspections to verify compliance.

Indian manufacturers exporting Albendazole formulations to the Netherlands must meet the following GMP standards:

• GMP Certification: Facilities must hold valid GMP certificates recognized by the EMA.

• Approved Facilities: As of 2024, 105 GMP certificates were issued to Indian manufacturing sites.

• Recent Inspections and Actions: In 2024, five GMP non-compliance statements were issued to Indian facilities, indicating areas requiring corrective actions.

Several regulatory changes have impacted Indian pharmaceutical exports to the Netherlands:

• Revised Schedule M in India: In January 2024, India's Ministry of Health and Family Welfare updated Schedule M to align with WHO GMP standards, enhancing quality controls across manufacturing processes.

• Extended Compliance Deadlines: Small and medium-sized enterprises (SMEs) in India were granted an extension until December 31, 2025, to comply with the revised Schedule M standards.

• Increased Regulatory Scrutiny: In November 2025, the Drugs Controller General of India (DCGI) directed state authorities to enforce updated GMP rules strictly, with non-compliant units facing potential closure.

These developments underscore the importance of stringent quality standards and regulatory compliance for Indian exporters aiming to supply Albendazole formulations to the Netherlands.

Albendazole is a broad-spectrum anthelmintic used to treat various parasitic infections in humans and animals. In the Netherlands, the demand for Albendazole formulations is influenced by factors such as the prevalence of parasitic infections, healthcare spending, and veterinary applications. While specific market size data for Albendazole in the Netherlands for 2024-2025 is not readily available, the country's robust healthcare infrastructure and comprehensive insurance coverage ensure access to necessary medications, including Albendazole formulations. The Netherlands imports Albendazole formulations, as indicated by the trade data, but also has domestic pharmaceutical manufacturing capabilities that may produce these medications.

Pharmaceutical products under HS code 30049099, including Albendazole formulations, are subject to a 0% Most-Favored-Nation (MFN) import duty rate in the Netherlands. Additionally, these products are exempt from import duties, facilitating their importation. There are no specific Free Trade Agreements (FTAs) between India and the Netherlands that affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on Albendazole formulations from India.

India is a significant supplier of Albendazole formulations to the Netherlands, accounting for 9.2% of India's total Albendazole formulation exports, valued at $6.6 million USD across 74 shipments. The top Indian exporters include Mepro Pharmaceuticals Private Limited and Medopharm. The primary buyers in the Netherlands are organizations such as Vitamin Angels and Rhenus BV. While specific data on other major countries supplying Albendazole to the Netherlands is not provided, India's competitive pricing and established pharmaceutical industry position it as a key player in this market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume. The country's pharmaceutical industry is supported by a vast network of manufacturing facilities, many of which are approved by international regulatory bodies such as the US FDA and WHO-GMP. For instance, Alembic Pharmaceuticals received final approval from the US FDA for Albendazole Tablets USP, 200 mg, in September 2024. This approval underscores India's capability to produce high-quality Albendazole formulations. The cost advantages in India stem from economies of scale, lower labor costs, and a well-established supply chain, enabling the production of finished dosage forms like tablets, capsules, and syrups at competitive prices.

When comparing Albendazole formulations from India, China, and the European Union, several factors come into play:

• Price per Unit: As of February 2026, the price of Albendazole in India was approximately $21.75 per kilogram, reflecting a slight decrease of 0.3%. Chinese manufacturers offer Albendazole tablets at prices ranging from $0.3 to $0.9 per piece. European manufacturers typically have higher production costs, leading to higher prices for Albendazole formulations.

• Quality Perception and Regulatory Acceptance: Indian pharmaceutical companies have a strong track record of meeting international quality standards, with numerous facilities approved by the US FDA and WHO-GMP. This compliance ensures that Indian Albendazole formulations are well-accepted in the Netherlands and other regulated markets. Chinese manufacturers have made significant strides in quality, but some European buyers may still perceive a gap compared to Indian products. EU manufacturers are known for high-quality standards; however, their higher costs can be a limiting factor.

• Supply Reliability: Indian manufacturers have demonstrated a reliable supply chain for Albendazole formulations, supported by robust manufacturing capacities and established export channels. Chinese suppliers have improved in this area but may face challenges related to regulatory scrutiny and geopolitical factors. EU manufacturers offer reliable supply but at higher costs.

The India-Netherlands supply chain for Albendazole formulations has proven to be reliable, with Indian manufacturers possessing substantial production capacities. For example, Granules India Limited's subsidiary, Granules Life Sciences Private Limited, received US FDA approval for its Hyderabad facility in November 2025, enhancing its finished dosage manufacturing capabilities. Packaging and cold chain logistics are well-developed, ensuring the integrity of Albendazole formulations during transit. Indian manufacturers have a strong compliance record with international regulatory standards, minimizing the risk of supply disruptions. While no significant supply disruptions have been reported recently, buyers should stay informed about potential regulatory changes or geopolitical developments that could impact the supply chain.

For buyers in the Netherlands sourcing Albendazole formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Albendazole formulations.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among suppliers. Establish clear agreements on order sizes to align with your demand forecasts and storage capabilities.

• Payment Terms: Standard payment terms in India-Netherlands pharmaceutical trade often include letters of credit (LC) or advance payments. Negotiate terms that balance cash flow considerations with supplier trust.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of regulatory approvals (such as US FDA and WHO-GMP certifications), and assessment of quality control systems.

• Regulatory Compliance: Ensure that the Albendazole formulations comply with the Netherlands' regulatory requirements, including proper labeling, documentation, and adherence to pharmacovigilance standards.

By implementing these strategies, buyers can establish a robust and reliable supply chain for Albendazole formulations from India.

By adhering to this comprehensive framework, Netherlands companies can effectively qualify Indian suppliers of Albendazole formulations, ensuring compliance with EU regulations and safeguarding product quality.